BrokerDealer Banks Bagged in IPO Mess: Finra Claims Conflict of Interest is Widespread

Brokerdealer.com blog update courtesy of excerpt from Bloomberg LP and reporters Leslie Picker and Dakin Campbell

conflictWall Street brokerdealers are changing the way they pitch for IPOs as investment banks prepare to settle with regulators, people with knowledge of the matter said, following claims analysts inflated estimates to win business for their banks.

The settlement with the Financial Industry Regulatory Authority, or Finra, which may be announced next month, will focus on meetings between analysts and companies ahead of their IPOs, said the people, who asked not to be identified because the information is private. At least seven banks, including Goldman Sachs Group Inc. and JPMorgan Chase & Co. (JPM), may be asked to pay a fine of about $50 million collectively as part of an agreement, the people said.

“We cannot confirm the existence of enforcement investigations or related matters,” Nancy Condon, a spokeswoman for Finra, said in a statement.

Continue reading

No Sweating This Biotech IPO; Dermira Prices 7.8mil Share Offering

Brokerdealer.com blog update courtesy of Renaissance Capital

Dermira, a biotech targeting skin conditions such as psoriasis, excessive sweating and acne, raised $125 million by offering 7.8 million shares at $16, the high end of the range of $14 to $16. Dermira plans to list on the NASDAQ under the symbol DERM. Dermira initially filed confidentially on 6/26/2014. BrokerDealers Citi and Leerink Partners acted as lead managers on the deal.

The Redwood City company led by CEO Tom Wiggins priced its shares at $16, the high end of its target range. It jumped by more than 10 percent Friday when it began trading on Nasdaq with the symbol of DERM. But it finished the day at $15.55, down almost 3 percent.

Despite $68 million in accumulated deficits and no revenue, the company had the best IPO of the three from the Bay Area this week. Together, they are the first companies in the region to go public since late July. Before pricing the shares, Dermira boosted the amount of stock offered by 46 percent.

Rottapharm, an Italian Drug Maker, Sets Price Range for IPO

BrokerDealer.com/blog update courtesy of extracts from today’s NYT DealBook

LONDON — The Italian drug maker Rottapharm said on Tuesday that it expected an initial public offering (IPO) of its shares later this month to value the company at up to 1.8 million euros, or about $2.46 billion.

ROTTAPHARM

Rottapharm, which operates under the name Rottapharm|Madaus, said that it expected to price its offering of 50 million shares at €7.25 to €9 a share. The bottom end of the price range would value the company at about €1.45 billion.

The offering represents about 25 percent of Rottapharm’s share capital, and it expects to list on the Mercato Telematico Azionario of the Borsa Italiana exchange in Milan. The company said on Tuesday that Italian securities regulators had signed off on its listing.

“Through the IPO, we will have the opportunity to present to the financial community the innovative and distinctive values of our business model,” Luca Rovati, Rottapharm’s chairman and chief executive, said in a statement. “Our entry into the capital markets is consistent with our growth strategy through new acquisitions, the launch of new products and expansion into new markets.”

About 5 percent of the offering, or about 2.5 million shares, will be sold to retail investors in Italy. The rest will be sold to institutional investors. The offer can be increased by up to another 10 million shares, depending on demand.

The shares are being sold by an investment vehicle controlled by the Rovati family, Rottapharm’s owners. The family will remain the drug maker’s largest shareholder after the offering.

The offer period is expected to end on July 10.

Founded in 1961, Rottapharm is the maker of Dona, which is used to manage pain associated with osteoarthritis; Legalon, a treatment for liver disorders; and Reparil, an anti-inflammatory and pain reducer. The company employs more than 2,000 employees in 85 countries worldwide.

The full article can be found at NYT DealBook.

Markit Heads to IPO Market, Wall Street BrokerDealers All Smiles

wsj logoBelow BrokerDealer.com blog news extract courtesy of the Wall St. Journal.

One of the biggest financial service industry IPOs of the season (as well as any other industry initial public offering of the season) is scheduled to launch on Thursday, and, as noted by the WSJ, Wall Street’s biggest banks are in line for a payday of up to a billion dollars from Markit Ltd.’s share float, as they cash out part of their stakes in the financial-data firm and divvy up the underwriting fees.

The 12 financial institutions that rank among the London company’s top shareholders expect to raise as much as $1.02 billion selling shares Wednesday at as much as $25 apiece, a rare bit of good news at a time of sluggish revenue, soft trading activity and regulatory scrutiny. The largest sellers are expected to be Bank of America Corp. BAC 0.00% , Citigroup Inc. C +0.29% and Deutsche Bank AG DBK.XE +0.49% , with Bank of America selling seven million shares to raise up to $176 million, according to filings.

The firm’s largest holders—an employee-benefits trust, private-equity firm General Atlantic and Singapore state-owned investment company Temasek Holdings Pte Ltd.—aren’t selling their shares, according to regulatory filings. The Canada Pension Plan Investment Board is considering buying $450 million worth of the shares, the filings said.

The offering, which begins trading Thursday, could give the financial-information company a $4.5 billion market value, highlighting Markit’s evolution in the years since the financial crisis and investors’ thirst for data on derivatives, bonds, loans and foreign-exchange markets.

“Markit started with a great idea, which was to create a central pricing service in what were at the time very rapidly growing credit markets,” said Mark Beeston, a former board member and founder of financial-technology venture-capital firm Illuminate Financial Management.

At the same time, the banks that have backed Markit since its founding more than a decade ago have been jockeying for position in selling the offering to the public. The deal is expected to raise as much as $1.1 billion altogether.

The company and the banks are discussing a fee pool of about 4% on the IPO, which would amount to as much as $45 million if the deal is priced at the top of the range, people familiar with the matter said.

The banks skirmished over their roles as the IPO was in its planning stages, according to some of the people familiar with the matter.

For the full story, please click here to visit the WSJ.

BrokerDealers & Bankers Cashing In on IPO Boom

Below Brokerdealer.com blog news extract courtesy of FT.com

Investment banks are cashing in on a boom in global stock market listings this year amid a resurgence of initial public offerings from Europe and Asia. Worldwide IPO fees of $3.15bn for the year to date are up nearly two-thirds from the same period a year ago, according to Thomson Reuters and Freeman Consulting.

The amount garnered in the Americas has risen slightly from $1.25bn to $1.31bn. Fees from these deals in the Asia-Pacific region jumped by almost three times to $853m, and more than doubled in Europe.

IPOs have been a bright spot for banks as volatility in secondary markets vanished, putting pressure on trading revenues. The CBOE Vix equity volatility index this month fell to a seven-year low.

The listings market in the US has been strong for a few years, experiencing a pullback this spring after overheating at the start of the year. Stabilisation in southern Europe has served as a catalyst for a rebound in deals throughout the continent, while Asia has been choppy.

“When you see sovereign yields in Greece and Spain fall, it allows people to put good values on any solid European company that may want to go public,” said Dan Simkowitz, co-head of global capital markets at Morgan Stanley.

The calendar is not necessarily dominated by southern Europe, but influenced by the “healing”, he said.

The IPO revival in Asia and Europe has clipped the global market share of fees for top earning banks as those with a strong regional presence in rebounding areas, such as UBS in Asia, move up the charts.

Sam Kendall, global head of equity capital markets at UBS, said: “Investors in Asia’s market are not just buying anything. The deals have to be priced sensibly, structured properly and have a good equity story. It’s the same thing all over the world.”

In Europe, the rush to list has been led by London where smaller banks such as Zeus Capital and Numis have used strong local profiles to gain market share against much larger competitors.  For the complete story, please visit FT.com